Paradigm Biocapital Advisors LP Crinetics Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $1.95 Billion
- Q1 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,946,168 shares of CRNX stock, worth $59.4 Million. This represents 3.34% of its overall portfolio holdings.
Number of Shares
1,946,168
Previous 1,910,761
1.85%
Holding current value
$59.4 Million
Previous $97.7 Million
33.19%
% of portfolio
3.34%
Previous 3.73%
Shares
11 transactions
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$284 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$210 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$190 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$190 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$156 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.64B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...